Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform

Jan 1, 2022·
Brian MacKenna
,
Nicholas a Kennedy
,
Amir Mehrkar
,
Anna Rowan
,
James Galloway
,
Julian Matthewman
,
Kathryn E Mansfield
,
Katie Bechman
,
Mark Yates
,
Jeremy Brown
,
Others
· 0 min read
Type
Publication
The Lancet Rheumatology